Travere Acquires Everest For $1.1 Billion
Travere has acquired Everest for $1.1 billion to strengthen its rare kidney disease and Btk inhibitor programs.
Topics
Developing
- 883d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 883d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 883d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 883d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Bluesky Social
“Travere acquires Everest for $1.1B to strengthen rare #RareKidneyDiseases #BtkInhibitor #PharmaceuticalAcquisition”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade